Opendata, web and dolomites

IMI-PainCare SIGNED

Improving the care of patients suffering from acute or chronic pain

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "IMI-PainCare" data sheet

The following table provides information about the project.

Coordinator
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG 

Organization address
address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117
website: www.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://imi-paincare.eu/
 Total cost 23˙200˙771 €
 EC max contribution 11˙225˙271 € (48%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) coordinator 974˙588.00
2    Universitätsklinikum Jena DE (Jena) participant 1˙681˙833.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙494˙132.00
4    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 971˙328.00
5    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 663˙750.00
6    AARHUS UNIVERSITET DK (AARHUS C) participant 555˙712.00
7    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 552˙487.00
8    UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA IT (ROMA) participant 528˙287.00
9    CONSULTECH TECHNOLOGIEBERATUNG GMBH DE (BERLIN) participant 435˙312.00
10    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 393˙750.00
11    INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC PT (PORTO) participant 351˙901.00
12    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 337˙037.00
13    KING'S COLLEGE LONDON UK (LONDON) participant 293˙807.00
14    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 288˙952.00
15    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA ES (VALENCIA) participant 257˙066.00
16    CLINIQUES UNIVERSITAIRES SAINT-LUC BE (BRUXELLES) participant 217˙043.00
17    HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ FI (HELSINKI) participant 201˙250.00
18    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) participant 167˙413.00
19    CHILDREN'S HOSPITAL CORPORATION US (BOSTON) participant 165˙667.00
20    MRC SYSTEMS GMBH MEDIZINTECHNISCHE SYSTEME DE (HEIDELBERG) participant 144˙000.00
21    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 123˙500.00
22    ACTUAL ANALYTICS LTD UK (EDINBURGH) participant 114˙412.00
23    REGION HOVEDSTADEN DK (HILLEROD) participant 57˙500.00
24    NEUROSCIENCE TECHNOLOGIES SLP ES (Barcelona) participant 50˙953.00
25    EUROPEAN PAIN FEDERATION EFIC BE (MACHELEN) participant 31˙250.00
26    PROMPTLY - SOFTWARE SOLUTIONS FOR HEALTH MEASURES, LDA PT (TROFA) participant 30˙000.00
27    MICHIGAN STATE UNIVERSITY US (EAST LANSING, MICHIGAN) participant 29˙548.00
28    EUROPEAN SOCIETY OF ANAESTHESIOLOGY AISBL BE (BRUXELLES) participant 25˙000.00
29    EUROPEAN SOCIETY OF REGIONAL ANAESTHESIA AND PAIN THERAPY CH (GENEVE) participant 25˙000.00
30    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) participant 21˙483.00
31    AALBORG UNIVERSITET DK (AALBORG) participant 18˙770.00
32    ENDOMETRIOSIS.ORG LTD UK (LONDON) participant 7˙510.00
33    PELVIC PAIN SUPPORT NETWORK UK (POOLE) participant 7˙510.00
34    STICHTING INTERNATIONAL PAINFUL BLADDER FOUNDATION NL (NAARDEN) participant 7˙510.00
35    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
36    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
37    ESTEVE PHARMACEUTICALS, SA ES (BARCELONA) participant 0.00
38    GRUNENTHAL GMBH DE (AACHEN) participant 0.00
39    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
40    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00

Map

 Project objective

There is a very high need for improving the management of pain. Acute and persistent pain of different origins represent a common medical, social, and economic burden, and its pharmacotherapy is often inadequate. To advance management of pain patients and support decision making in clinical practice, more predictive assessments of treatment success are needed. The development of analgesics is onerous because promising preclinical data often do not translate into the clinic. Improved pharmacodynamic biomarkers could define whether nociceptive signalling is adequately modulated by a new drug, so increasing the chance of successful translation and greatly reducing the risk in initiating clinical development. Further, the pathophysiology of chronic pelvic pain indications is poorly understood and no adequate preclinical models are available, precluding focused preclinical research and leaving affected patients with little hope of relief. IMI-PainCare aims at making advances in these three pain areas in a complementary manner. Three subprojects will address specific scientific challenges. Subproject PROMPT will identify Patient Reported Outcome Measures as tools to standardise assessments of treatment success of acute and chronic pain in Real World conditions and controlled trials, and so improve its management; subproject BioPain will validate the translatability of pharmacodynamic biomarkers and PK-PD modelling in pain pathways of healthy subjects and preclinical species, thereby offering tools to improve drug development; subprojectTRiPP will identify biomarkers and novel therapeutic pathways of clinical phenotypes of patients with chronic pelvic pain, which after back-translation, can improve how preclinical models reflecting human diseases. The goal of IMI-PainCare is to improve the care of patients with acute or chronic pain by providing a toolbox to streamline the development process for novel analgesic drugs and to improve treatment quality in clinical practice.

 Deliverables

List of deliverables.
Review of clinical and preclinical literature on biomarkers and medication Documents, reports 2020-04-11 08:24:55
Study synopsis and protocol uploaded to EudraCT Documents, reports 2020-04-11 08:24:55
Consensus on final trial designs for BioPainRCT1, BioPainRCT2, BioPainRCT3 and BioPainRCT4 Documents, reports 2020-04-11 08:24:55

Take a look to the deliverables list in detail:  detailed list of IMI-PainCare deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 B. Dias, F. Cruz, A. Charrua
Bladder pain induced by chronic stress is mediated by a systemic increase of nerve growth factor involving the activation of adrenoceptors
published pages: e1967, ISSN: 1569-9056, DOI: 10.1016/s1569-9056(19)31425-3
European Urology Supplements 18/1 2020-04-11
2018 A. Stouffs, L. Lebrun, A. Mouraux
IMI-PAINCARE, BIOPAIN : validation chez l’homme de nouveaux biomarqueurs fonctionnels pour le développement pharmacologique de traitements de la douleur
published pages: 230-231, ISSN: 1011-288X, DOI: 10.3166/dea-2018-0041
Douleur et Analgésie 31/4 2020-04-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMI-PAINCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMI-PAINCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More